Charlotte Bronnimann
A5021155687- Glioma Diagnosis and Treatment
- Neuroblastoma Research and Treatments
- Brain Metastases and Treatment
- Radiomics and Machine Learning in Medical Imaging
- Meningioma and schwannoma management
- Ocular Oncology and Treatments
- PARP inhibition in cancer therapy
- Neurofibromatosis and Schwannoma Cases
- Lung Cancer Treatments and Mutations
- Cancer Research and Treatments
- Cancer, Stress, Anesthesia, and Immune Response
- Prostate Cancer Treatment and Research
- Immunotherapy and Immune Responses
- Cancer Genomics and Diagnostics
- Bone Tumor Diagnosis and Treatments
- Cancer Immunotherapy and Biomarkers
- Inflammatory Myopathies and Dermatomyositis
- Nutrition and Health in Aging
- Advanced Electron Microscopy Techniques and Applications
- Cancer, Lipids, and Metabolism
- Radiopharmaceutical Chemistry and Applications
- Cancer therapeutics and mechanisms
- Nanoplatforms for cancer theranostics
- Radiation Therapy and Dosimetry
- Cancer Treatment and Pharmacology
Hôpital Saint-André
2018-2025
Centre Hospitalier Universitaire de Bordeaux
2018-2025
Hospices Civils de Lyon
2018-2024
Université de Bordeaux
2021-2024
Centre National de la Recherche Scientifique
2024
Centre Léon Bérard
2024
Centre de Recherche en Cancérologie de Lyon
2024
Université Claude Bernard Lyon 1
2024
Inserm
2024
Abstract Background No systemic treatment has been established for meningioma progressing after local therapies. Methods This randomized, multicenter, open-label, phase II study included adult patients with recurrent WHO grade 2 or 3 meningioma. Patients were 2:1 randomly assigned to intravenous trabectedin (1.5 mg/m2 every weeks) standard of care (LOC). The primary endpoint was progression-free survival (PFS). Secondary endpoints comprised overall (OS), objective radiological response,...
Abstract Background: Radio-chemotherapy remains the mainstay of glioblastoma first-line treatment after extended surgery, but prognosis is still poor. PARP inhibitors like olaparib may improve outcomes. We implemented a phase 1-2a trial to assess safety and efficacy combined with standard radio-chemotherapy as in unresected patients. herein present results 1. Methods: Based on Stupp regimen, two sequential dose escalations were performed distinguish radiotherapy period maintenance for...
<div>AbstractPurpose:<p>Tropomyosin receptor kinase (TRK) fusions are detected in less than 2% of central nervous system tumors. There limited data on the clinical course affected patients.</p>Experimental Design:<p>We conducted an international retrospective cohort study patients with TRK fusion–driven tumors.</p>Results:<p>A total 119 were identified. The median age at time diagnosis was 4.5 years. majority reported to have a histology consistent...
<p>Supplementary Figure S1. Diagram of population patients.</p>
<p>Supplementary Figure S2. A) Hazard ratio for progression or death according to clinical characteristics. B) LGG: Low-grade glioma, HGG: High-grade glioma</p>
<p>Supplementary Data S1. Definition of response, Description response criteria used by sites to evaluate tumor extend resection, resection sites.</p>
Abstract Background Brain tumors represent one of the main causes cancer‐related mortality in young patients. Among them, oligodendrogliomas (OG) are adult‐type diffuse gliomas with best prognosis. Nevertheless, characterization these population remains poorly documented. Our objective was to characterize adults under 40 years age grade 3 OG POLA cohort. Methods Clinical data prospectively collected for all patients registered between April 2009 and August 2021 were extracted from national...
<p>A. Progression-free (left) and overall (right) survival among the 30 patients enrolled in two sequential olaparib dose-escalations of trial.</p>
<p>C. Progression-free (left) and overall (right) survival for first second olaparib dose-escalation cohorts of the trial. was defined as time elapsed from treatment start to RANO progression or death any cause (whichever occurs first); Overall cause.</p>
<p>B. Progression-free (left) and overall (right) survival according to MGMT status among the patients enrolled in two sequential olaparib dose-escalations of trial.</p>
<p>Magnetic Resonance Imaging (gadolinium, FLAIR and perfusion sequences from left to right) at baseline (top) 60 months (bottom) after start of treatment in first line a partially resected glioblastoma patient.</p>
<div>AbstractPurpose:<p>Radiochemotherapy remains the mainstay of glioblastoma (GBM) first-line treatment after extended surgery, but prognosis is still poor. PARP inhibitors like olaparib may improve GBM outcomes. We implemented a phase I to IIa trial assess safety and efficacy combined with standard radiochemotherapy as in patients unresected GBM. herein present results I.</p>Patients Methods:<p>Based on Stupp regimen, two sequential dose escalations were performed...
Abstract Background Based on preclinical studies showing that IDH-mutant (IDHm) gliomas could be vulnerable to PARP inhibition we launched a multicenter phase 2 study test the efficacy of olaparib monotherapy in this population. Methods Adults with recurrent IDHm high-grade (HGGs) after radiotherapy and at least one line alkylating chemotherapy were enrolled. The primary endpoint was 6-month progression-free survival rate (PFS-6) according response assessment neuro-oncology criteria....
PURPOSE Patients with IDH-mutant 1p/19q-codeleted grade 3 oligodendroglioma (O3 IDHmt/Codel ) benefit from adding alkylating agent chemotherapy to radiotherapy (RT). However, the optimal regimen between procarbazine, 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU), and vincristine (PCV) temozolomide (TMZ) remains unclear given lack of randomized trial data comparing both regimens. METHODS The objective was assess overall survival (OS) progression-free (PFS) associated first-line PCV/RT...
Incidence and characteristics of pseudoprogression in isocitrate dehydrogenase-mutant high-grade gliomas (IDHmt HGG) remain to be specifically described.We analyzed explored the possibility misdiagnosis IDHmt HGG patients, treated with radiotherapy (RT) (with or without chemotherapy [CT]), included French POLA network. Pseudoprogression was patients MRI available for review (reference cohort, n = 200). estimated this cohort an independent (control 543) based on progression-free survival...
2004 Background: Patients with IDH-mutant 1p/19q-codeleted grade 3 oligodendroglioma (O3 IDHmt/Codel ) benefit from adding alkylating chemotherapy to radiotherapy (RT). However, the optimal regimen between Procarbazine, CCNU, and Vincristine (PCV) Temozolomide (TMZ) remains unclear given lack of randomized trial data comparing both regimens. Methods: The objective was assess overall (OS) progression-free (PFS) survival associated first-line PCV/RT versus TMZ/RT in patients diagnosed O3 . We...
Abstract Purpose: TRK fusions are detected in less than 2% of central nervous system tumors. There limited data on the clinical course affected patients. Experimental design: We conducted an international retrospective cohort study patients with fusion-driven CNS Results: 119 were identified. The median age at time diagnosis was 4.5 years. majority reported to have a histology consistent high-grade glioma (HGG) (57.1%) followed by low-grade (LGG) (27.7%). Pediatric had better prognosis...